Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma : A Nordic Multicenter Comparative Study

Show full item record



Permalink

http://hdl.handle.net/10138/161481

Citation

Haugvik , S-P , Janson , E T , Osterlund , P , Langer , S W , Falk , R S , Labori , K J , Vestermark , L W , Gronbaek , H , Gladhaug , I P & Sorbye , H 2016 , ' Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma : A Nordic Multicenter Comparative Study ' , Annals of Surgical Oncology , vol. 23 , no. 5 , pp. 1721-1728 . https://doi.org/10.1245/s10434-015-5013-2

Title: Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma : A Nordic Multicenter Comparative Study
Author: Haugvik, Sven-Petter; Janson, Eva Tiensuu; Osterlund, Pia; Langer, Seppo W.; Falk, Ragnhild Sorum; Labori, Knut Jorgen; Vestermark, Lene Weber; Gronbaek, Henning; Gladhaug, Ivar Prydz; Sorbye, Halfdan
Contributor: University of Helsinki, Clinicum
Date: 2016-05
Language: eng
Number of pages: 8
Belongs to series: Annals of Surgical Oncology
ISSN: 1068-9265
URI: http://hdl.handle.net/10138/161481
Abstract: This study aimed to evaluate the role of surgery for patients with high-grade pancreatic neuroendocrine carcinoma (hgPNEC) in a large Nordic multicenter cohort study. Prior studies evaluating the role of surgery for patients with hgPNEC are limited, and the benefit of the surgery is uncertain. Data from patients with a diagnosis of hgPNEC determined between 1998 and 2012 were retrospectively registered at 10 Nordic university hospitals. Kaplan-Meier curves were used to compare the overall survival of different treatment groups, and Cox-regression analysis was used to evaluate factors potentially influencing survival. The study registered 119 patients. The median survival period from the time of metastasis was 23 months for patients undergoing initial resection of localized nonmetastatic disease and chemotherapy at the time of recurrence (n = 14), 29 months for patients undergoing resection of the primary tumor and resection/radiofrequency ablation of synchronous metastatic liver disease (n = 12), and 13 months for patients with synchronous metastatic disease given systemic chemotherapy alone (n = 78). The 3-year survival rate after surgery of the primary tumor and metastatic disease was 69 %. Resection of the primary tumor was an independent factor for improved survival after occurrence of metastatic disease. Patients with resected localized nonmetastatic hgPNEC and later metastatic disease seemed to benefit from initial resection of the primary tumor. Patients selected for resection of the primary tumor and synchronous liver metastases had a high 3-year survival rate. Selected patients with both localized hgPNEC and metastatic hgPNEC should be considered for radical surgical treatment.
Subject: SMALL-CELL CARCINOMA
CONSENSUS GUIDELINES
LIVER METASTASES
TUMORS
MANAGEMENT
SURVIVAL
CHEMOTHERAPY
NEOPLASMS
DIAGNOSIS
RESECTION
3122 Cancers
3126 Surgery, anesthesiology, intensive care, radiology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
s10434_015_5013_2.pdf 419.5Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record